Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2003. Start Trial.
Date Value
December 31, 2025 47.80%
September 30, 2025 45.38%
June 30, 2025 46.08%
March 31, 2025 44.29%
December 31, 2024 43.33%
September 30, 2024 41.30%
June 30, 2024 42.43%
March 31, 2024 42.61%
December 31, 2023 43.63%
September 30, 2023 41.01%
June 30, 2023 43.60%
March 31, 2023 41.29%
December 31, 2022 42.56%
September 30, 2022 42.30%
June 30, 2022 43.55%
March 31, 2022 36.41%
December 31, 2021 41.29%
September 30, 2021 42.35%
June 30, 2021 41.63%
March 31, 2021 37.21%
December 31, 2020 45.83%
September 30, 2020 49.63%
June 30, 2020 51.05%
March 31, 2020 50.16%
December 31, 2019 50.81%
Date Value
September 30, 2019 51.88%
June 30, 2019 52.85%
March 31, 2019 51.12%
December 31, 2018 52.57%
September 30, 2018 53.75%
June 30, 2018 54.17%
March 31, 2018 53.75%
December 31, 2017 54.55%
September 30, 2017 56.24%
June 30, 2017 55.51%
March 31, 2017 51.76%
December 31, 2016 53.90%
September 30, 2016 56.52%
June 30, 2016 55.42%
March 31, 2016 52.75%
December 31, 2015 55.55%
September 30, 2015 54.48%
June 30, 2015 55.03%
March 31, 2015 52.92%
December 31, 2014 54.73%
September 30, 2014 56.17%
June 30, 2014 54.92%
March 31, 2014 52.23%
December 31, 2013 56.71%
September 30, 2013 54.32%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Kao Corp. 39.51%
Kosé Holdings Corp. 69.91%
euglena Co., Ltd. 68.61%
Milbon Co., Ltd. 64.05%
Rohto Pharmaceutical Co., Ltd. 55.72%